Introduction: Cowden syndrome patients are at an increased risk of developing differentiated thyroid carcinoma (DTC). There are limited studies of thyroid cancer biology within this population. We aimed to describe the frequency and progression of DTC in this population. Method: We reviewed all patients with clinically or genetically confirmed Cowden syndrome treated at our institution between 1979 and 2017. Presentation, operative details, pathology, and adjuvant treatment for all thyroid diseases were analyzed. Results: Forty-seven patients were identified. Thirty-seven received a clinical diagnosis while 10 tested positive on genetic testing for the PTEN gene. Average follow-up time was 10 years. Twenty-three patients underwent a total thyroidectomy. Nine patients were diagnosed with thyroid cancer, with a mean age of 28.5 years, 4 cases of the follicular variant of papillary thyroid cancer (PTC), 4 of PTC, and 1 of cystic PTC. One patient required an interval lateral neck dissection but no patients developed distant metastasis. Fourteen patients underwent thyroidectomy, 12 due to follicular adenoma, Hürthle cell adenoma, or multinodular goiter, 1 due to Graves’ disease, and 1 who elected to undergo a prophylactic thyroidectomy. No mortality was associated with thyroid cancer in these patients. Conclusion: Patients with Cowden syndrome are at a significantly increased risk of developing DTC and have a younger age of onset. In this study, 20% of the patients with Cowden syndrome were diagnosed with DTC, but distant metastasis and overall mortality were absent. Clinical features were similar to those of sporadic DTC, proving that, apart from screening, Cowden syndrome-related DTC can be treated in similar fashion.

1.
Tan
MH
,
Mester
JL
,
Ngeow
J
,
Rybicki
LA
,
Orloff
MS
,
Eng
C
.
Lifetime cancer risks in individuals with germline PTEN mutations
.
Clin Cancer Res
.
2012
Jan
;
18
(
2
):
400
7
.
[PubMed]
1078-0432
2.
Kameyama
K
,
Takami
H
,
Miyajima
K
,
Mimura
T
,
Hosoda
Y
,
Ito
K
, et al.
Papillary carcinoma occurring within an adenomatous goiter of the thyroid gland in Cowden’s disease
.
Endocr Pathol
.
2001
;
12
(
1
):
73
6
.
[PubMed]
1046-3976
3.
Pilarski
R
,
Eng
C
.
Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome
.
J Med Genet
.
2004
May
;
41
(
5
):
323
6
.
[PubMed]
0022-2593
4.
Milas
M
,
Mester
J
,
Metzger
R
,
Shin
J
,
Mitchell
J
,
Berber
E
, et al.
Should patients with Cowden syndrome undergo prophylactic thyroidectomy?
Surgery
.
2012
Dec
;
152
(
6
):
1201
10
.
[PubMed]
0039-6060
5.
Haugen
BR
.
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: what is new and what has changed?
Cancer
.
2017
Feb
;
123
(
3
):
372
81
.
[PubMed]
0008-543X
6.
Kimura
ET
,
Nikiforova
MN
,
Zhu
Z
,
Knauf
JA
,
Nikiforov
YE
,
Fagin
JA
.
High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma
.
Cancer Res
.
2003
Apr
;
63
(
7
):
1454
7
.
[PubMed]
0008-5472
7.
Laury
AR
,
Bongiovanni
M
,
Tille
JC
,
Kozakewich
H
,
Nosé
V
.
Thyroid pathology in PTEN-hamartoma tumor syndrome: characteristic findings of a distinct entity
.
Thyroid
.
2011
Feb
;
21
(
2
):
135
44
.
[PubMed]
1050-7256
8.
Hall
JE
,
Abdollahian
DJ
,
Sinard
RJ
.
Thyroid disease associated with Cowden syndrome: A meta-analysis
.
Head Neck
.
2013
Aug
;
35
(
8
):
1189
94
.
[PubMed]
1043-3074
9.
Ngeow
J
,
Mester
J
,
Rybicki
LA
,
Ni
Y
,
Milas
M
,
Eng
C
.
Incidence and clinical characteristics of thyroid cancer in prospective series of individuals with Cowden and Cowden-like syndrome characterized by germline PTEN, SDH, or KLLN alterations
.
J Clin Endocrinol Metab
.
2011
Dec
;
96
(
12
):
E2063
71
.
[PubMed]
0021-972X
10.
Cameselle-Teijeiro
J
,
Fachal
C
,
Cabezas-Agrícola
JM
,
Alfonsín-Barreiro
N
,
Abdulkader
I
,
Vega-Gliemmo
A
, et al.
Thyroid Pathology Findings in Cowden Syndrome: A Clue for the Diagnosis of the PTEN Hamartoma Tumor Syndrome
.
Am J Clin Pathol
.
2015
Aug
;
144
(
2
):
322
8
.
[PubMed]
0002-9173
11.
Grebe
SK
,
Hay
ID
.
Thyroid cancer nodal metastases: biologic significance and therapeutic considerations
.
Surg Oncol Clin N Am
.
1996
Jan
;
5
(
1
):
43
63
.
[PubMed]
1055-3207
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.